We hypothesized that a daily subcutaneous injection
Selleck Rapamycin of 0.7 mg rhGH administered between 1 and 3 pm for 40 weeks in HIV-infected patients would (1) decrease VAT without accompanying decreases in abdominal or femoral subcutaneous adipose tissue (SAT), (2) decrease trunk fat mass without decreases in limb fat mass, and (3) cause no decrease in glucose tolerance. Outcomes, which were changes in VAT, SAT, trunk fat mass, limb fat mass, percentage of limb fat and glucose tolerance, were compared in the two study groups and also stratified according to the presence of HALS. After written informed consent had been obtained, subjects were eligible to participate in the study if they were HIV-infected, male, Caucasian, weight-stable, 21 to 60 years of age, on a HAART regimen for at least 12 months, and classified as either having or not having BMS-354825 clinical trial HALS, according to the clinical definition applied in The Lipodystrophy
Definition Case Study . Participants were required to have a viral load of <1000 HIV-1 RNA copies/mL, a CD4 count of >200 cells/L, a fasting plasma glucose value of <6.1 mM, a body mass index (BMI) of between 18.5 and 28 kg/m2, a calcium ion concentration of between 1.15 and 1.35 mM, a vitamin D concentration of >19 nM and a thyroid-stimulating hormone (TSH) concentration of between 0.1 and 10 mIU/L. Further, they were required not to have an HIV-wasting or current AIDS-defining disease, any other serious chronic disease or cancer, a previous myocardial infarction, diabetes mellitus, a serious psychiatric disease, drug or alcohol abuse, or therapy with systemic steroids, sex hormones, rhGH or immunomodulating or anti-lipid therapy. The study was
CHIR-99021 mw approved by the regional scientific ethical committee, the Danish Medicines Agency, and the Danish Data Protection Agency, and was registered at http://www.clinicaltrials.gov (NCT 00119769). The study was carried out according to good clinical practice (GCP), monitored by the GCP unit at Copenhagen University Hospital, and inspected by the Danish Medicines Agency. All study visits took place at the Clinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark, and were performed at identical intervals in the placebo and GH groups. All visits were performed in the morning, and patients were instructed to fast for 12 h and abstain from moderate and vigorous physical activity for 3 days before each visit. Eligible patients were randomized on a three-to-two basis to receive 0.7 mg/day of either rhGH (Genotropin) or placebo (both from Pfizer A/S, Ballerup, Denmark). The Capital Regional Pharmacy, Denmark, computer-generated a randomization list with patient numbers corresponding to either placebo or rhGH treatment, and packed and labelled the study medication. The randomization was stratified according to the presence or absence of HALS, with an equal number in each group.